The Pharmacy Times® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.
April 12th 2024
Both dual primary endpoints—progression-free survival and overall survival—were met with durvalumab.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung Cancer
1.5 Credits / Lung Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
October 25th 2023Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Read More
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
October 25th 2023Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.
Read More
Novel Oral Medication Reduces Risk of Death by 76% in Patients With ALK-Positive Lung Cancer
October 20th 2023The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.
Read More
FDA Approves Pembrolizumab Resectable Non–Small Cell Lung Cancer
October 17th 2023Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.
Read More
Topline Data Demonstrate Survival Improvement With Amivantamab-vmjw for NSCLC
September 29th 2023The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.
Read More
Cancer Diagnoses Significantly Decreased in First Few Months of COVID-19 Pandemic
September 14th 2023Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.
Read More
Supplemental Biologics License Application Submitted to Expand Approval of Rybrevant for NSCLC
August 29th 2023The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.
Read More
Study: Multilevel Data Model Helps Estimate Likelihood of Delays in Cancer Treatment
August 24th 2023In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.
Read More
Data Show Durable Efficacy With Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC
August 18th 2023Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.
Read More